IDI FUNDING OPPORTUNITIES

The Infectious Diseases Institute (IDI) is committed to advancing infectious disease research, regardless of disciplinary focus (i.e., IDI welcomes applications for the below funding mechanisms from all colleges and all disciplines):

Applicants for the below funding opportunities are required to be IDI members. Not a member?  JOIN THE INSTITUTE →

Given the current COVID-19 pandemic, the deadlines for the IDI Interdisciplinary Research Seed Grant Application and the IDI Trainee Transformative Research Grant Application are being extended to Wednesday, April 15, 2020.

Interdisciplinary Research Seed Grant Application and Guidelines (downloadable PDF)
Seed grant funding is available for research initiatives intended to foster interdisciplinary collaborative efforts and to enhance competitiveness for defined extramural support for the purposes of growth.

Trainee Transformative Research Grant Application and Guidelines (downloadable PDF)
Research grant funding is available for trainee driven small, up to $2,000, transformative research grants intended to foster new collaborative efforts and to increase a project's impact, ability to publish and/or how the research might lead to novel discoveries.

Internal Event Funding Application and Guidelines (downloadable PDF)
Events funding is available for activities that are interdisciplinary, support student or trainee development, advance an infectious diseases or microbiology area of study, and/or increase awareness of Ohio State’s Infectious Diseases Institute, and its infectious diseases and microbiology community.

Targeted Investment Application and Guidelines (downloadable PDF)
Funding is available for targeted investments intended to support initiatives that have the potential to be uniquely transformative; or significantly enhance key, long-term strategic priorities identified by the institute’s executive committee.

 

ADDITIONAL FUNDING RESOURCES AND TOOLS

Ohio State Office of Research Funding Opportunities and Research Database

National Science Foundation Outreach Activities

Academic Research Funding Strategies

Research Development and Grant Writing Newsletter
(Ohio State login required)

Looking for a NIH Program Official in Your Research Area?

For years researchers have used the Matchmaker feature in NIH RePORTER to identify NIH-funded projects similar to their supplied abstracts, research bios, or other scientific text. Matchmaker was recently enhanced to make it just as easy to identify NIH program officials whose portfolios include projects in your research area.

After entering your scientific text (up to 15,000 characters), Matchmaker will analyze the key terms and concepts to identify up to 500 similar projects. Those projects will continue to show on the Projects tab with handy charts to visualize the results and quickly filter identified projects by Institute/Center, Activity Code, and Study Section. A new Program Official tab identifies the program officials associated with the matched projects and includes its own filters for Institute/Center and Activity Code. From the list of program officials you are one click away from their contact information and matched projects in their portfolios. Never before has it been so easy to answer the question “Who at NIH can I talk to about my research?”  Learn more

INTERNAL FUNDING OPPORTUNITIES

CCTS at Nationwide Children's Hospital Integrating Special Populations Pilot Program

call for proposals

 The Center for Clinical and Translational Science at Nationwide Children’s Hospital is seeking applications for a pilot funding opportunity, sponsored by the CCTS Integrating Special Populations (ISP) Program. The ISP Pilot Program offers up to $40,000 in funding per annual award cycle, to either one investigator or multiple investigators at NCH/OSU, for an award period of one calendar year (12 months). The goal is to support research initiatives that involve groups that are frequently underrepresented in clinical and translational research.

Please note that the ISP Program's Executive Committee on Lifespan Research (ECLR) is also available to provide research consultations at no-cost. If you are an OSU or NCH faculty member who is interested in meeting with someone from the ECLR for assistance with integrating special populations in your research, please contact us

CCTS Trial Innovation Network

Call for proposals

Continuous submission

The Trial Innovation Network is looking for study projects with: Principal Investigators who are willing to partner with the TIN through the project lifecycle; innovations in operations; multiple sites; inclusion of many populations; and academic evidence to improve clinical trial design. If you are interested in submitting a proposal to the TIN, you must contact the OSU Hub Liaison Team first for an initial review of your proposal, brief consultation, and review by local scientific review committee. Please contact Angela Sow, TIN Hub Liaison Team Administrator at 614-247-7732 with questions. 

KL2 Mentored Career Development Grant

Offered annually

The OSU Center for Clinical & Translational Science (CCTS) KL2 Program supports the career development of assistant professors who have made a commitment to conduct either patient-oriented or translational research. The KL2 Award is available for a period of three years (contingent on satisfactory progress), with two years of CCTS funding and a third from the scholar’s home college. Junior faculty Ohio State University or Nationwide Children's Hospital on the tenure-track or clinical track with fewer than three years since their initial appointment are eligible to apply.

Batelle Grant Competition Call for Proposals

Offered annually

The Batelle Engineering, Technology and Human Affairs (Betha) Endowment is calling for proposals from Ohio state full-time assistant, associate and full professors. The annual competition awards three to six projects ($10,000 to $60,000) examining the impact of science and technology on individuals and society. More Information

EXTERNAL FUNDING OPPORTUNITIES

DARPA Young Faculty Award

Offered annually

The Defense Advanced Research Projects Agency (DARPA) Young Faculty Award (YFA) program aims to identify and engage rising stars in junior faculty positions in academia and equivalent positions at non-profit research institutions and expose them to Department of Defense (DoD) and National Security challenges and needs. In particular, this YFA will provide high-impact funding to elite researchers early in their careers to develop innovative new research directions in the context of enabling transformative DoD capabilities. The long-term goal of the program is to develop the next generation of scientists and engineers in the research community who will focus a significant portion of their future careers on DoD and National Security issues. DARPA is particularly interested in identifying outstanding researchers who have previously not been performers on DARPA programs, but the program is open to all qualified applicants with innovative research ideas.

Investigators in the Pathogenesis of Infectious Disease (PATH)

Offered annually

The Burroughs Welcome Fund's Investigators in the Pathogenesis of Infectious Disease (PATH) award provides $500,000 over five years to support accomplished investigators at the assistant professor level to study pathogenesis with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters.

NIAID Clinical Trial Planning Grant (R34 Clinical trial not allowed)

Deadlines are: May 12, 2020; September 14, 2020; January 12, 2021; May 14, 2021; September 13, 2021; January 14, 2022; and May 13, 2022.

This FOA encourages applications that propose planning, design, and preparation of documentation necessary for implementation of investigator-initiated clinical trials.  Sufficient pre-clinical data to support the planning of the clinical trial should be available prior to submission of the R34 grant application. Access the PAR-19-281 application here

New Innovators Awards (DP2 Clinical trial not allowed)

Deadlines: October 14, 2020; October 13, 2021

NIAID plans to support exceptionally creative postdoctoral investigators who propose highly innovative research projects with the potential for unusually high impact in the mission of NIAID. The NIAID DP2 program is available to both U.S. and non-U.S. citizen postdoctoral investigators, and the award will only be activated once the applicant has obtained a U.S. faculty position. Applicants for this award must have a research or clinical doctorate. Funding is $300K in direct costs per year for up to five years. Complete the application PAR-19-296 here

Research Projects to Improve the Predictive Value of Animal Models in Recapitulating Human Immunity to Influenza Infection and Vaccination (clinical trial not allowed)

Deadline for R21: June 18, 2020; June 18, 2021; Deadline for R01: June 10, 2020; June 10, 2021

The purpose of these FOAs is to support research to improve existing animal models or develop novel animal models that more accurately represent influenza immunity in humans, with an emphasis on increasing the predictive value of models for evaluating novel universal influenza vaccines. If the research is at a formative stage, consider the R21. If the research is already significantly developed and supported by preliminary data, the R01 may be more appropriate. 
R21 - PAR-19-247
R01 - PAR-19-248

Dissemination and Implementation Research in Health (R01 Clinical trial optional)
The purpose of this FOA is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within the scope of the mission of one of the participating Institutes. Standard deadline dates apply. PAR-19-274 application.

AFRI Foundational and Applied Science Program
The AFRI Foundational and Applied Science Program supports grants in six AFRI priority areas to advance knowledge in both fundamental and applied sciences important to agriculture. The six priority areas are: Plant Health and Production and Plant Products; Animal Health and Production and Animal Products; Food Safety, Nutrition, and Health; Bioenergy, Natural Resources, and Environment; Agriculture Systems and Technology; and Agriculture Economics and Rural Communities. Research-only, extension-only, and integrated research, education and/or extension projects are solicited in this Request for Applications (RFA).

Growing Convergence Research (GCR)

NSF 19-551

Deadlines February 3, 2020 and annually thereafter

Growing Convergence Research is a new NSF-wide program. As one of NSF’s 10 Big Ideas, convergence research is a means for solving vexing research problems, in particular, complex problems focusing on societal needs. It entails integrating knowledge, methods, and expertise from different disciplines and forming novel frameworks to catalyze scientific discovery and innovation. Convergence Research has two primary characteristics:

  • Research driven by a specific and compelling problem. Convergence Research is generally inspired by the need to address a specific challenge or opportunity, whether it arises from deep scientific questions or pressing societal needs.
  • Deep integration across disciplines. As experts from different disciplines pursue common research challenges, their knowledge, theories, methods, data, research communities and languages become increasingly intermingled or integrated. New frameworks, paradigms or even disciplines can form sustained interactions across multiple communities.

This GCR solicitation targets multi-disciplinary team research that crosses directorate or division boundaries and is currently not supported by NSF programs, initiatives and research-focused Big Ideas. Proposers must make a convincing case that the research to be conducted is within NSF's purview and cannot be supported by existing NSF programs and multidisciplinary initiatives. Up to 5 years in two phases - $1.2M for years 1-2 and additional $2.4M for years 3-5.

Microbial-based Cancer Therapy - Bugs as Drugs

PAR-19-193 (R01 Clinical Trial Not Allowed)

PAR-19-194 (R21 Clinical Trial Not Allowed)

Deadlines Standard dates

The overall purpose of this funding opportunity announcement (FOA) is to stimulate development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms for cancer treatment and to complement or synergize with current therapies. This FOA will support basic, mechanistic and preclinical studies in cell culture and animal models in accordance with the state of the science. Applicants responding to this FOA are encouraged to address both the microbial and the tumor aspects of microbial-based cancer therapy.

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer

PAR-19-198 (R01 Clinical Trial Not Allowed)

PAR-19-199 (R21 Clinical Trial Not Allowed)

Deadlines June 10, 2020; November 6 2020; June 10, 2021; November 8, 2021

This FOA will support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses.  Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation. 

Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

PAR-19-158

Many NIH Institutes including NIAID

Deadlines Standard dates (expires January 8, 2022)

This FOA encourages collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. Within the broad aims of this FOA, NIAID is especially interested in the following scientific areas:

  • Quantitative, predictive models of complex interactions of the immune system, e.g., during development; in response to pathogens or vaccines; during the initiation, development, or progression of immune-mediated diseases; or in early-stage development of interventions for immune-mediated diseases
  • Novel bioengineering approaches, including imaging, for analysis of immune cell phenotype and function in response to infectious or immune-mediated diseases in target organs and tissues; delivery of immunomodulatory agents, adjuvants, or antigens; or development and characterization of novel biomaterials with immunostimulatory/adjuvant properties
  • Biodosimetry biomarkers, technologies, and devices to inform triage and treatment strategies of large populations following a radiological or nuclear incident
  • Home-based, self-administered tests for detecting HIV in the acute phase of infection
  • Simple and accurate assays to quantify the persistent HIV reservoir
  • In vitro tissue models for infectious diseases that mimic human biological structures, recapitulate pathophysiology, and incorporate components critical to pathogenesis and host response—simple enough for use in basic science or sufficiently robust for use in preclinical studies of candidate therapeutics or vaccines
  • Multiplex integrated sample-to-answer platforms to rapidly diagnose infectious diseases and identify the causative pathogen and its drug sensitivities

Grand Challenges

Environmental niches of Salmonella Typhi

Bill & Melinda Gates Foundation

In this new grand challenge, Gates solicits proposals to examine the environmental niches of S. Typhi. We are interested in understanding: (1) Survival of S. Typhi in the context of the soil and water microbiomes; (2) Survival of S. Typhi within other organisms; and (3) Impact of environmental niches on the development of antibiotic resistance in S. Typhi. What we are interested in funding:

  • Studies of S. Typhi in the context of soil and water microbiomes, with clear implications for survival, virulence, or antibiotic resistance.
  • Examining survival of S. Typhi within or in the presence of free-living protozoans
  • Examining the role of the environment (soil, water, residual antibiotics) in the development of AMR in S. Typhi
  • Transcriptome analysis and mutagenesis of S. Typhi to identify genes associated with particular environmental niches.

In all cases, the relevance of findings to the epidemiology of typhoid must be clear. If interested in submitting a proposal, contact Jason Phillips, Director of Foundation Relations, at Phillips.814@osu.edu.

Tick-Borne Disease Research Program

Investigator-Initiated Research Award, Idea Award, and Career Development Award

DOD/CDMRP Army

The Defense Appropriation provides $5M to the Department of Defense Tick-Borne Disease Research Program (TBDRP) to support innovative, high-impact tick-borne disease research. The TBDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. Applications submitted to the TBDRP must address at least one of the following specific Focus Areas in Lyme disease and other tick-borne diseases:

  • Diagnosis, including accurate diagnostics and biomarkers and diagnostic biomarkers
  • Pathogenesis, including pathogenic mechanisms, complex biology of Lyme borrelia in the host (beyond in vitro studies), and underlying mechanisms of persistent symptoms
  • Prevention, including safe and effective human vaccines for tick-borne diseases, identification, validation, and/or improvement of tick-targeted prevention and control interventions, and ecology of understudied tick-borne disease vectors and reservoirs with emphasis on how it relates to human risk.
  • Treatment including antibiotic combinations and/or therapeutic options for treating acute and persistent illness

2020 Seeding Solutions Grants

Call for Pre-Proposals

Foundation for Food and Agriculture Research (FFAR)

Pre-proposal submission deadline: February 26, 2020 (submitting a pre-application is required to submit a full application) // Full application invitation: April 22, 2020 // Full applications due: June 24, 2020

FFAR, through its flagship competitive grant program, Seeding Solutions, has issued an open call for innovative research projects that support one of FFAR’s Challenge Areas and fosters unique partnerships. Grantees are required to provide matching funds from non-federal sources and identify an innovation that addresses an intractable problem in food and agriculture within one of FFAR’s Challenge areas.

Investigator-Initiated Research Award

W81XWH19PRMRPIIRA

DOD/CDMRP Army

Offered annually

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY19 PRMRP Topic Areas– including antimicrobial resistance, emerging infectious diseases, Hepatitis B, and tuberculosis. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies. Clinical trials are not permitted. Relevance to the healthcare needs of military service members, veterans, and beneficiaries is key.

Discovery Award

W81XWH19PRMRPDA

DOD/CDMRP Army

Offered annually

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design. Relevance to the healthcare needs of military service members, veterans, and beneficiaries is key. Award maximum $200,000.

Technology/Therapeutic Development Research Award

W81XWH19PRMRPTTDA

DOD/CDMRP Army

Offered annually

The Technology/Therapeutic Development Award  is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY19 PRMRP Topic Areas– including antimicrobial resistance, emerging infectious diseases, Hepatitis B, and tuberculosis. Products in development should be responsive to the healthcare needs of military service members, veterans, and/or beneficiaries.

Focused Program Award

W81XWH19PRMRPFPA

DOD/CDMRP Army

Offered annually

Focused Program Award applications must describe a unifying, overarching challenge that will be addressed by a set of research projects. The overarching challenge must be relevant to a critical problem or question in the field of research and/or patient care in at least one of the FY19 PRMRP Topic Areas– including antimicrobial resistance, emerging infectious diseases, Hepatitis B, and tuberculosis. Applications shall include multiple, distinct research projects led by individual project leaders that address complementary aspects of the overarching challenge. Applicants are strongly encouraged to submit a minimum of four research projects; additional studies are allowed. Award maximum $10,000,000.

Clinical Trial Award

W81XWH19PRMRPCTA

DOD/CDMRP Army

Offered annually 

The Clinical Trial Award supports the rapid implementation of clinical trials with potential to have significant impact on at least one of the FY19 PRMRP Topic Areas– including antimicrobial resistance, emerging infectious diseases, Hepatitis B, and tuberculosis. Projects can be designed to evaluate promising new products, drugs or biologics, devices etc. Funding must support a clinical trial (pilot Phase 0 through large-scale trials) and cannot be used for preclinical studies. Award amount isn’t limited. 

Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)

PA-19-077

NIAID

Standard dates (expires January 8, 2022)

This FOA supports early phase translational research that will generate new malaria vaccine candidates suitable for further downstream development and clinical evaluation.  This research opportunity encourages studies that will lead to discovery of new vaccine candidates that prevent infection, ameliorate disease, and/or interrupt transmission caused by human malaria parasites, especially P. falciparum and P. vivax. 

Pharmaceutics Research Starter Grants

RFP

PhRHMA Foundation

Offered annually

This award offers financial support to individuals beginning independent research careers in pharmaceutics (including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, and pharmaceutical biotechnology) at the faculty level. Funding is $100,000 for one year.

Gut Microbiome, Yogurt and Probiotics Dannon Fellowship Grant

RFP

Offered annually 

Grants of $25,000 for a graduate student with strong interest in exploring the gut microbiome, probiotics, and/or yogurt. To be eligible, applicants must be a citizen of the United States; a current, full-time graduate student; and prepared to do his/her research at an accredited U.S. institution during the 2019-20 academic year.

Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)

PA-19-068

NIAID

Standard dates (expires January 8, 2022) 

This FOA supports projects that utilize open-access data, alone or in combination with other datasets, to address knowledge gaps in basic and/or clinical research in infectious diseases. 

Processing and Presentation of Non-Conventional MHC Ligands

PA-19-067 (R01 Clinical Trial Not Allowed)

PA-19-066 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires January 8, 2022) 

These FOAs support research to characterize antigen processing and presentation mechanisms used in the generation of novel peptidic and non-peptidic ligands presented by classical and non-classical MHC class I and class II molecules, and to determine the contribution of these unique antigenic ligands to: protective immune responses to infectious pathogens and/or vaccines; pathogen-associated immune pathogenesis; and/or in the induction/progression or prevention of immune-mediated diseases.

Advancing Development of Rapid Fungal Diagnostics

PA-19-080 (R01 Clinical Trial Not Allowed)

PA-19-081 (R21 Clinical Trial Not Allowed)

NIAD

Standard dates (expires January 8, 2022) 

The purpose of this FOA is to support the development of rapid, sensitive, specific, simple, and cost-effective diagnostics for primary health-care settings (hospitals and point-of-care).

Innovation in Regulatory Science

RFP

Burroughs Wellcome Fund

Offered Annually 

This program funds the development of new methodologies or innovative approaches in regulatory science that will ultimately inform the regulatory decisions the FDA and others make. Investigators are strongly encouraged to address the FDA’s following strategic priorities:

  • Accelerating Delivery of New Treatments to Patients
  • Improving Pediatric and Child Health
  • Protecting Against Emerging Infectious Diseases and Terrorism
  • Enhancing Safety and Health Through Informatics
  • Protecting the Food Supply
  • Modernizing Safety Testing
  • Meeting the Challenges for Regulating Tobacco

Faculty interested in learning more or applying to this opportunity should contact Jason Phillips (phillips.814@osu.edu) in the Office of Foundation Relations.

Grand Challenges Explorations:

Application of Metagenomic Next Generation Sequencing to Detect and Identify Pathogens

Bill & Melinda Gates Foundation

Offered annually 

Grand Challenges Explorations is an initiative that awards initial grants of USD $100,000, and successful projects are eligible to receive follow-on funding of up to USD $1 million. This call for proposals seeks fundamentally new strategies for manufacturing gut microbial biotherapeutics to achieve manufacturing efficiency and cost reductions necessary for global health applications. We are particularly open to high risk, unproven concepts that could yield novel systems. We also encourage approaches that may be carried out in low- and middle- income countries (LMIC) and proposers currently working in these settings.

Engaging Men in HIV Testing, Prevention, and Care

PA-19-042 (R01 Clinical Trial Optional)

PA-19-050 (R21 Clinical Trial Optional)
NIAID, NIMH

Standard AIDS due dates

The purpose of these FOAs is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care.

Health Outcomes Program

RFP

PhRMA Foundation

Offered annually 

Health Outcomes research spans a broad spectrum of issues related to healthcare delivery, from studies evaluating the effectiveness of a pharmaceutical intervention to the impact of reimbursement policies on outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of ways in which results of outcomes research are disseminated to providers or consumers to encourage behavior change. Through the program, one-year grants of up to $100,000 will be awarded to assist individuals beginning an independent research career in health outcomes at the faculty level.

Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21 Clinical Trial Not Allowed)

PAR-18-923

NIAID

Deadline January 14, 2021

This FOA supports innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Guérin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals.

Michelson Prizes

Program information

Human Vaccines Project

The Michelson Prizes are scientific awards of $150,000 given annually to young investigators who are applying disruptive research concepts and inventive processes to advance vaccine and immunotherapy research for major global diseases.

Increasing Demand for Vaccination Services
Program Link

Bill and Melinda Gates Foundation

Offered annually

Within this call to increase demand for vaccination services, and thus increase the number of children vaccinated globally, we are looking for innovative ideas in the following specific areas:

(1) Novel approaches for providing practical knowledge about vaccines and vaccination services to caregivers

(2) Novel ideas for improving the convenience and/or caregiver seeking of vaccination services

If interested in responding, contact Jason Phillips, Director of Foundation Relations, at Phillips.814@osu.edu.

Tools and Technologies for Broad-Scale Pest and Disease Surveillance of Crop Plants in Low-Income Countries
Program Link

Bill and Melinda Gates Foundation

Offered annually

The goal of this topic is to solicit innovative tools and technologies for crop pests and disease surveillance over large geographic regions in low-income countries. We are looking for tools and approaches that have the potential to transform crop pest and disease surveillance globally, with a focus on low-income countries.

If interested in responding, contact Jason Phillips, Director of Foundation Relations, at Phillips.814@osu.edu.

New Approaches for Manufacturing Gut Microbial Biotherapeutics
Program Link

Gates Foundation

Offered annually 

This call for proposals seeks fundamentally new strategies for manufacturing gut microbial biotherapeutics to achieve manufacturing efficiency and cost reductions necessary for global health applications. We are particularly open to high risk, unproven concepts that could yield novel systems. We also encourage approaches that may be carried out in low- and middle- income countries (LMIC) and proposers currently working in these settings.

If interested in responding, contact Jason Phillips, Director of Foundation Relations, at Phillips.814@osu.edu.

Innovations Driving Programmatic Performance in Immunization: Service Experience and Data use + Measurement
Program Link

Bill and Melinda Gates Foundation

Offered annually 

Gates is looking for innovative ideas in the following areas:

1) Innovative ideas for improving the measurement approaches for immunization data (e.g., process, equity, coverage indicators) with a focus on data use by program managers, triangulation across data sources, and methods to measure and quantify data use. We are interested in approaches to measure through both routine systems as well as periodic systems.

2) Innovative ideas that improve service delivery and experience for caregivers and/or healthcare workers during the vaccination session.

If interested in responding, contact Jason Phillips, Director of Foundation Relations, at Phillips.814@osu.edu

Research Supplements to Promote Diversity in Health-Related Research

PA-18-906 (Admin Supp - Clinical Trial Not Allowed)

Multiple NIH Institutes

Deadline January 14, 2021

Do you know a bright student or postdoc who is an underrepresented minority? NIH offers administrative supplements of up to $100,000 per year to support diversity participation on a wide variety of grant awards.

HIV/AIDS High Priority Drug Abuse Research

PAS-18-915 (R01 Clinical Trial Optional)

NIDA

Standard AIDS due dates

This Funding Opportunity Announcement) is being issued to stimulate high priority research relevant to drug misuse and/or use disorders and HIV/AIDS. High priority topic areas include reducing the incidence of HIV/AIDS, next generation therapies, research toward a cure, research on HIV-associated comorbidities, research to reduce health disparities, with additional details on priorities found here.

Ecology and Evolution of Infectious Diseases (EEID)

NSF 18-581

NSF (with additional support from NIH, USDA and others)

Deadline November 18, 2020 // Third Wednesday in November, Annually Thereafter

The multi-agency EEID program supports research on the ecological, evolutionary, and social principles and processes that influence the transmission dynamics of infectious diseases. The central theme must be quantitative or computational understanding of pathogen transmission dynamics, in order to discover principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants.

Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences

NSF 18-566

NSF and NIGMS

Submission windows: September 1-18 2020 and annually thereafter

NIGMS and the Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences at the NSF plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need for promoting research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support existing ones. NIGMS and DMS anticipate making 12 to 20 awards totaling up to $5 million per year.

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

PA-18-902

NIH including NCI, NCCIH, and ODS

Standard due dates (expires September 8, 2021)

The purpose of this FOA is to (1) accelerate translational and clinical studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and (2) understand the underlying mechanisms of their action(s) and variability in responses to these interventions. This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

CNS-Targeted Drug Delivery Strategies for HIV (R01 Clinical Trial Not Allowed)
PAR-18-895

NIAID and NIMH

Deadline January 7, 2021

The purpose of this FOA is to support studies with a focus on developing drug delivery strategies that target the Central Nervous System (CNS) for better suppression of Human Immunodeficiency Virus (HIV) and reservoir reduction.  Applications are sought proposing multidisciplinary efforts to enhance delivery of antiretroviral (ARV) drugs and biologics into CNS compartments, maintaining a good balance between therapeutic effect and toxicity. Collaborative research partnerships are strongly encouraged but not required.

PhRMA Foundation Grants

Research Starter Grants

Pharmaceutics

Pharmacology/Toxicology

Offered annually 

Research Starter Grants: Research Starter Grants help promising young scientists advance their research projects by providing $100,000 for one year to individuals beginning independent research careers at the faculty level.

Pharmaceutics: The aim of this program is to offer financial support to individuals beginning independent research careers in pharmaceutics—including basic pharmaceutics, biopharmaceutics, pharmaceutical technology, and pharmaceutical biotechnology—at the faculty level.
Pharmacology/Toxicology: These awards intend to encourage multidisciplinary training to apply the perspective of molecular, cell, and systems biology to pharmacology and toxicology research. Their scope includes basic drug action studies, detection of cellular responses to drugs at the gene level that create opportunities to optimize individualized drug therapy, and the corresponding evaluation of pharmaceuticals in human and clinical populations.

Individuals interested in applying should contact Jason Phillips (phillips.814@osu.edu), Director of Foundation Relations

NASA iTech

Submission deadline March 27, 2020 

NASA leads the way in scientific discovery of Earth, other worlds and the cosmos. Advancing new technologies in aeronautics and space systems, NASA's missions expand the frontiers of human experience and allow American industry to cultivate a growing space marketplace.

Through NASA iTech, we reach beyond traditional partnerships into early, independent innovation. NASA iTech helps us identify the innovations we will need in the future (and the people behind them). We connect innovators with investors who can help propel them forward, and industry leaders who can partner or invest in the technologies.

NASA iTech Forum is planned for October 23-26, 2018.

Research to Advance Vaccine Safety

PA-18-872 (R21 Clinical Trial Not Allowed)

PA-18-873 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires September 8, 2021)

These FOAs support research that will contribute to the overall understanding of vaccine safety, in particular studies that address: 1) characterization of physiological and immunological responses to vaccines and vaccine components, including different adjuvants; 2) how genetic variations affect immune/physiological responses that may impact vaccine safety; 3) identification of risk factors e.g., infection history, predisposition to or presence of allergic and/or autoimmune disease and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines; 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases; or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan.

Advancing Research Needed to Develop a Universal Influenza Vaccine

PA-18-858 (R21 Clinical Trial Not Allowed)

PA-18-859 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires September 8, 2021)

These FOAs support research activities that will advance the plan “A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases,” including efforts to: 1) improve understanding of transmission, natural history and pathogenesis of influenza virus infection; 2) characterize influenza immunity and correlates of immune protection; and 3) support rational design of universal influenza vaccines.

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects

R21 Clinical Trial Not Allowed - PAR-18-846

R01 Clinical Trial Not Allowed - PAR-18-845

NCI, NIDCR, NIDA, and NIEHS

Deadlines June 27, 2020, October 26, 2020; June 25, 2021

This funding announcement encourages research evaluating the biological mechanisms whereby ENDS aerosols affect the normal and disease states relevant to human cells, tissues or organs. Of relevance to IDI, NIDCR is interested in the analysis of effects of e-cigarettes on factors responsible for the maintenance of oral homeostasis such as cytokine production and downstream signaling pathways, immune cell function, and oral microbiome.

Immune Response to Arthropod Blood Feeding (R21 Clinical Trial Not Allowed)

PAR-18-860

NIAID

Deadline October 15, 2020

The scientific objectives of this initiative are (1) to understand the immunological events in the vertebrate host, which occur during and after blood feeding by hematophagous arthropods, at the bite site (skin) and systemically; (2) to identify and characterize the immune modulatory properties of arthropod salivary components; and (3) to understand the immunological events in the hematophagous arthropods following a blood meal.

Rapid Outcomes from Agricultural Research (ROAR)

Details here

Foundation for Food and Agriculture Research

Ongoing opportunity 

This grant provides up to $150,000 in a one-year grant to combat new or emerging pest and pathogen outbreaks that threaten the U.S. food and agriculture systems. In the event of a pest or pathogen outbreak, submit a one-page concept note to FFAR outlining (1) the research team, including academic scientists, industry representatives and/or government officials (consortium required), (2) the source and amount (up to $150,000) of matching funds for the project and (3) a brief description of the pest or pathogen threat and why it should be considered for rapid funding. FFAR will use the concept note to decide whether or not to invite submission of a full application.

Submit your concept note to Tim Kurt at tkurt@foundationfar.org. Meritorious concepts will be asked to submit a full proposal.

Expanding Extramural Research Opportunities at the NIH Clinical Center (U01 Clinical Trial Optional)

PAR-18-879

NIAID

Deadline December 3, 2020

The purpose of this FOA is to support extramural investigator-initiated clinical research in partnership with the NIH Clinical Center in Bethesda, MD. This new FOA will leverage the resources (inpatient and outpatient) and assets of the NIH Clinical Center (e.g., scientific and clinical expertise, nursing, beds, critical care services, ambulatory care services, laboratories, imaging, biostatistics, protocol development, regulatory guidance, clinical trials management and safety oversight) in accelerating the discovery and translation from laboratory to clinic of therapies for infectious (including primary immunodeficiency diseases), immunologic, and allergic diseases. Specifically, it will support hypothesis-driven mechanistic studies alone or within clinical projects employing Phase 0, 1, and/or 2a clinical trial designs.   

Polio Research Grants

Call for proposals

Global Polio Eradication Initiative (GPEI)

GPEI seeks to fund research projects that will contribute significantly to polio eradication from disciplines including basic science research, operational research, mathematical modeling projects, and epidemiological studies/clinical studies.

Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)

PA-18-876

NIDCR, NCI, NIAMS, NIDA, and NIH Office of Dietary Supplements

Standard dates (expires September 8, 2021)

The purpose of this FOA is to: (1) stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. Basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function are encouraged.

Global Antimicrobial Stewardship

Call for Grant Applications (CGA)

Offered annually 

Pfizer provides independent grants to support initiatives that accelerate the translation of clinical science into quality patient care. Track 2 awards are designed to close knowledge gaps through educational strategies and improved competence in specified clinical areas. This call for applications related to global antimicrobial stewardship programs includes:

  1. Antimicrobial Stewardship education including:
  • Education on how to institute stewardship programs
  • “Hands-on” preceptorship training in appropriate stewardship
  • Support of external group dedicated to stewardship
  1. Projects that make existing data available more broadly to aid healthcare professionals in their stewardship efforts 

Research Pilot and Feasibility Award

Cure Cycstic Fibrosis Columbus (C3)

Offered annually 

P&F grant applications must focus on basic and/or translational research questions that: 1) are relevant to the CFF and C3 research missions; and 2) address existing or emerging C3 focus areas. The proposed research must utilize at least two of the three C3 Research Cores (see attachment). Interested parties are invited to submit a Letter of Intent. The C3 Internal Advisory Board will review the Letters of Intent and will invite applicants to submit a full-length P&F grant. The full-length P&F grants will be reviewed and the applicants will be invited to submit a revised P&F grant. Revised P&F grants will be reviewed by the C3 Internal and External Advisory Boards.

Development of Therapeutic Products for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is the development of therapeutics for use in post-event settings following the intentional release of select pathogens, or in response to naturally-occurring outbreaks of infectious diseases caused by pathogens listed in the Technical Approach section. While proposals for the development of broad-spectrum therapeutics are encouraged, candidate therapeutics or lead series with a limited spectrum that target high-priority pathogens for which no standard clinical treatment exists or for which drug resistance poses a significant public health concern are eligible as proposed candidates/products or lead series

Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is the development of vaccines for scenarios associated with intentional release of a NIAID Category A, B, or C Priority Pathogen, or naturally-occurring outbreaks of infectious diseases caused by these pathogens or Zika virus (as a component of a multivalent vaccine for other pathogens such as a vaccine for Flavivirus family). Only proposed candidate products aimed at these pathogens are eligible. The candidate product(s) may also include an adjuvant that enhances the immune response (i.e., enhanced immunogenicity, decreased time, or reduced number of immunizations to achieve protective antibodies and/or increased efficacy). Adjuvants will be supported as components of the candidate product.

Collaborative Influenza Vaccine Innovation Centers (CIVICs)

NOT-AI-18-048

National Institute of Allergy and Infectious Diseases (NIAID)

The objective of this funding opportunity is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity ("universal influenza vaccines"). This funding will support iterative vaccine design based on detailed immunologic assessment of influenza vaccine candidates through pre-clinical animal studies, early phase clinical trials and healthy volunteer human challenge studies to advance the most promising vaccine candidates into Phase I/II clinical trials.

Small Research Grant Program (R03)

PA-18-794

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires July 6, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

NIOSH Research Grant Programs

Small Grants (R03) PAR-18-797

Exploratory/Developmental Grant Program (R21) PAR-18-798

Occupational Safety and Health Research (R01) PAR-18-769

Standard dates apply for future dates (expires November 18, 2023)

National Institute for Occupational Safety and Health (NIOSH) is an agency operating under the Centers for Disease Control and Prevention (CDC), with the mission of generating new knowledge in the field of occupational safety and health and transferring that knowledge into practice to prevent worker injury, illness and death. They fund a range of research including studies to reduce occupational exposure to infectious disease.

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)

PA-18-784

National Heart, Lung, and Blood Institute

Standard dates ( expires September 8, 2021

The objective of this FOA is to attract investigator-initiated multidisciplinary R01 research projects to define mechanistic interactions between the microbiome (gut/lung/oral or combinations) that influence normal physiology and pathophysiology of diseases within NHLBI's mission (see NHLBI Strategic Vision and mission). This FOA aims to address this gap in “causation,” leveraging the use of available biospecimens from existing cohorts and biobanks, using state of the art technologies (including high throughput sequencing, transcriptomics, proteomics, metabolomics, single cell profiles) and animal models, if applicable, with the goal to further our understanding of the complex microbiome-host interactions and functions.

Agriculture and Food Research Initiative Competitive Grants Program: Sustainable Agricultural Systems

RFA

USDA & National Institute of Food and Agriculture (NIFA)

Offered annually 

NIFA seeks creative and visionary applications that take a systems approach, and that will significantly improve the supply of abundant, affordable, safe, nutritious, and accessible food, while providing sustainable opportunities for expansion of the bioeconomy through novel animal, crop, and forest products and supporting technologies. These approaches must demonstrate current and future social, behavioral, economic, health, and environmental impacts. Additionally, the outcomes of the work being proposed must result in societal benefits, including promotion of rural prosperity and enhancement of quality of life for those involved in food and agricultural value chains from production to utilization and consumption.

Role of Gut Microbiome in Regulating Reproduction and Its Impact on Fertility Status in Women Living with and Without HIV

PA-18-838 (R01 - Clinical Trial Optional)

PA-18-839 (R21 Clinical Trial Optional)

NICHD

Standard dates (expires September 18, 2021)

Objective is to examine the role of the gut microbiome in regulating metabolism and reproduction, and its impact on fertility status. The overarching goal is to gain fundamental insight into the possible role of the gut microbiome in regulating reproduction through hypothalamo-pituitary-gonadal (HPG), hypothalamo-pituitary-adrenal (HPA), and hypothalamo-pituitary-thyroid (HPT) axes in the brain. The results of the study could lead to development of diagnostic markers (signature microbiomes) for reproductive and metabolic failure.

Approaches for Understanding Disease Mechanisms and Improving Outcomes in TB Meningitis (TBM) (R01 Clinical Trial Not Allowed)

PAR-18-822

NIAID and NIMH

Deadline September 4, 2020

This FOA will support hypothesis-based clinical and preclinical/non-clinical research studies focused on: 1) Identifying pathogenic and immunopathogenic mechanisms in the context of CNS-TB in in vitro and appropriate animal models that impact TBM disease development, progression, and outcomes, as well as the effect of HIV co-infection on these mechanisms; 2) Assessing molecular targets in pathogenic and immunopathogenic mechanisms leading to discovery or confirmation of targets for HDT; and 3) Evaluating new/repurposed antimicrobial drugs and/or dosing of current antimicrobials that are optimized for TBM treatment for use in combinations to more rapidly clear the infection.

HIV-Focused Population Surveys in Countries Supported Under the President's Emergency Plan for AIDS Relief (PEPFAR)

CDC-RFA-GH19-1941

CDC

This opportunity will provide funding and technical assistance for HIV-focused, household-based surveys in national and subnational general populations of all ages in PEPFAR countries. The secondary purpose is for HIV focused surveys and population size estimation of key and priority populations. These activities serve to assess program impact to inform national and local responses to HIV, mostly located in sub-Saharan Africa. These surveys estimate HIV prevalence and incidence, viral load, drug resistance, and other biomarkers, inform the uptake of prevention and treatment services, and estimate progress towards population-level UNAIDS 95-95-95 targets. The surveys may also measure diseases and health conditions related to HIV such as TB, hepatitis and syphilis to inform compatible public health action. This survey NOFO aims at generating high quality laboratory and interview data using standardized methods, strengthening local survey capacity, ensuring publicly accessible data to improve public health programs, and creating specimen repositories for future study. Key populations are sex workers, men who have sex with men, transgender women, people who inject drugs, and prisoners. Priority populations include country-specific groups shown to be at greater risk of HIV such as partners of sex workers, fisherfolk, and adolescent girls and young women.

The Role of Epitranscriptomics in Development and Disease

PAR-18-830 (R01 - Clinical Trial Not Allowed)

PAR-18-831 (R21 - Clinical Trial Not Allowed)

NICHD, NCI and NEI

Deadlines March 3, 2020, November 7, 2020, June 3, 2021

These FOAs promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions. (Note that – as always – proposals must be relevant to the scientific mission of the participating institutes.)

Agriculture and Food Research Initiative Competitive Grants Program: Foundational and Applied Science Program
RFA

USDA NIFA

Letter of Intent and Application Deadline: Varies by Program Area (see RFA for details)

Offered annually 

Applications are sought in the following priority areas, a number of which have relevance for infectious disease research. See the RFA for details.

  1. Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases
  2. Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
  3. Food safety, nutrition, and health (including Improving Food Safety and Understanding Antimicrobial Resistance)
  4. Bioenergy, natural resources, and environment;
  5. Agriculture systems and technology; and
  6. Agriculture economics and rural communities

NIAID Omnibus Broad Agency Announcement

NOT-AI-20-025

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, NIH, of the DHHS is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the following NIAID Divisions:

- Division of Allergy, Immunology, and Transplantation (DAIT), NIAID, NIH
- Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH

Approaches for Understanding Disease Mechanisms and Improving Outcomes in TB Meningitis (R01 Clinical Trial Not Allowed)

PAR-18-822

NIAID and NIMH

Deadline September 4, 2020

To support clinical and preclinical/non-clinical research to improve our understanding of disease mechanisms in tuberculosis meningitis and to improve therapy in the presence or absence of HIV co-infection.

Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required) PAR-18-630

NIAID, NIA and NIGMS

Deadline March 9 2020

This opportunity supports applications for conducting investigator-initiated, milestone-driven, long-term (6 or 7 year) incrementally funded clinical trials (all phases) and associated mechanistic studies. Examples of factors that may require a project period of 6-7 years include:

•Nature of disease under study, longer follow-up required to achieve clinical and mechanistic outcomes

•Number and diversity of study sites

•Number of participants necessary for study completion

•Availability of target pool for the study

•Known difficulty with participant recruitment and/or retention

•Complex regulatory requirements specific to the study

Robert E. Shope International Fellowship in Infectious Diseases
American Society of Tropical Medicine and Hygiene
Offered annually 
For more information, see list of previous recipients and Frequently Asked Questions.

Investigator Studies Program (MISP) for Infectious Disease

Merck

Due dates varies – see description below

The Investigator Studies Program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research. The current MISP areas in infectious disease are:

Antimicrobial Stewardship proposals accepted until June 1, 2020

Bacterial Infections proposals accepted until March 3, 2020

Clostridium difficile proposals accepted until June 15, 2020 

CMV proposals accepted until June 8, 2020 

HIV proposals accepted until September 17, 2019 

Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development
Grand Challenge RFP

Gates Foundation

The goal of this Grand Challenge is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic. Pilot Awards are $250,000 up to $2 million. Promising pilot projects may be invited to apply for up to $10 million. Interested applicants should contact Jason Phillips (Director, Foundation Relations, Phillips.814@osu.edu) as well as your sponsored programs officer. Jason’s team is available to discuss proposal ideas and review drafts.

Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development
PA-18-724 (R21 Clinical Trial Not Allowed)
PA-18-725 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires May 8, 2020) 

The purpose of this FOA is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

Small Research Grant Program (R03)

PA-18-794

Agency for Healthcare Research and Quality (AHRQ)

Standard dates (expires July 6, 2021)

AHRQ supports research whose short-term or long-term aim is to develop improved methods for preventing HAIs and to develop effective implementation strategies for HAI prevention in all health care settings. AHRQ is interested in studies to promote appropriate antibiotic use, reduce the transmission of resistant bacteria, and prevent HAIs in the first place.

NIOSH Research Grant Programs

Small Grants (R03) PAR-18-797

Exploratory/Developmental Grant Program (R21) PAR-18-798

Occupational Safety and Health Research (R01) PAR-18-769

National Institute for Occupational Safety and Health (NIOSH)

Standard dates (expires November 18, 2023) 

NIOSH is an agency operating under the Centers for Disease Control and Prevention (CDC), with the mission of generating new knowledge in the field of occupational safety and health and transferring that knowledge into practice to prevent worker injury, illness and death. They fund a range of research including studies to reduce occupational exposure to infectious disease.

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)

PA-18-784

National Heart, Lung, and Blood Institute

Standard dates (expires September 8, 2021)

The objective of this FOA is to attract investigator-initiated multidisciplinary R01 research projects to define mechanistic interactions between the microbiome (gut/lung/oral or combinations) that influence normal physiology and pathophysiology of diseases within NHLBI's mission (see NHLBI Strategic Vision and mission). This FOA aims to address this gap in “causation,” leveraging the use of available biospecimens from existing cohorts and biobanks, using state of the art technologies (including high throughput sequencing, transcriptomics, proteomics, metabolomics, single cell profiles) and animal models, if applicable, with the goal to further our understanding of the complex microbiome-host interactions and functions.

Agriculture and Food Research Initiative Competitive Grants Program: Sustainable Agricultural Systems

RFA

USDA NIFA

Offered annually 

NIFA seeks creative and visionary applications that take a systems approach, and that will significantly improve the supply of abundant, affordable, safe, nutritious, and accessible food, while providing sustainable opportunities for expansion of the bioeconomy through novel animal, crop, and forest products and supporting technologies. These approaches must demonstrate current and future social, behavioral, economic, health, and environmental impacts. Additionally, the outcomes of the work being proposed must result in societal benefits, including promotion of rural prosperity and enhancement of quality of life for those involved in food and agricultural value chains from production to utilization and consumption.

Antimicrobial Stewardship in the Asia-Pacific Region

RFP

Pfizer

Pfizer is seeking quality improvement research, health services research and/or educational research applications that identify and evaluate practices for successfully implementing key elements of antimicrobial stewardship programs within hospitals and other healthcare organizations.

Research Grants
Call for proposals

Cystic Fibrosis Foundation

Research grants are intended to support basic science research. Studies may be carried out at the subcellular, cellular, animal, or patient levels. To be considered, proposals must be hypothesis-driven and provide sufficient preliminary data to justify Cystic Fibrosis Foundation support. Support is available for $125,000 per year (plus 8 percent for indirect costs) for up to two years. Priority will be placed on those projects that propose to better understand the mechanisms behind disease pathophysiology and to develop strategies to prevent or treat CF.

Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required) 

PAR-18-633

NIAID

Deadlines May 13, 2020; September 14, 2020; January 13, 2021

This opportunity encourages cooperative agreement applications for implementation of investigator-initiated, milestone driven, high-risk clinical trials and mechanistic studies associated with high-risk clinical trials. A clinical trial is defined by NIH as a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes. In addition, any research study that will require regulatory oversight such as IND or IDE would be in scope.

Antibiotic Use & Resistance
Spring 2020 RFP

National Pork Board

Deadline February 25, 2020

Proposals are solicited in the areas of Alternatives to Antibiotics, Antibiotic Administration, and Mitigations. See RFP for additional details.

Rule of Life: Forecasting and Emergence in Living Systems (FELS)

The Dear Colleague Letter (DCL): Rule of Life: Forecasting and Emergence in Living Systems (FELS) section on conference proposal. The workshop proposals are due on June 1. I think conferences that focus on microbial topics and how they inform the rules of life would be a good way to move microbial science forward. Off the top of my head, I can think of workshops on the emergence of multicellularity from a unicellular life style, latency, dormancy, persistence in microbial ecology, and establishing phenotype from genotype in microbes may fit the DCL  Please find below the address of the webpage and the excerpt regarding the conferences:  

 https://nsf.gov/pubs/2018/nsf18031/nsf18031.jsp

RoL: FELS conference: These awards will provide up to one year of support for projects that do not exceed $100,000. PIs are encouraged to contact any relevant Program Director in a participating Directorate about suitability of the proposed conference prior to submission. RoL: FELS conference proposals may be submitted to any relevant program in a participating Directorate, but must include the prefix 'RoL:FELS' in front of the title. The deadline for submission of these proposals is June 1, 2018. received. RoL:FELS conference proposals should follow normal PAPPG guidance.

Contact Mamta Rawat, Ph.D., Program Director Physiological and Structural Systems Cluster, BIO/Integrative Organismal Systems, National Science Foundation, 2415 Eisenhower Avenue, Alexandria, VA 22314, Ph. 703-292-7265, for additional information. 

Investigator-Initiated Genomic Medicine Research
PAR-18-735 (R01 Clinical Trial Optional)
PAR-18-736 (R21 Clinical Trial Optional)

National Human Genome Research Institute

Deadlines June 19, 2020; October 20, 2020

This opportunity supports research opportunities that will advance our understanding of, and the implementation of, the use of genomic information about an individual to inform clinical care, and the health outcomes of that clinical use.

Centennial Travel Award in Basic Science Tropical Disease Research
American Society of Tropical Medicine and Hygiene
Offered annually 
For more information, see list of previous recipients and Frequently Asked Questions.

Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional) RFA-DA-19-003

NIDA

Deadline July 17, 2020

This initiative will support Omics studies (e.g. transcriptomic, epigenomic, epitranscriptomic, proteomic, metabolomic, nucleomic, high throughput imaging or functional testing, etc.) to address outstanding questions regarding HIV latency or reservoirs in the context of chronic substance use. These studies could be performed on tissues, body fluids, or single cells. The R61/R33 grant mechanism includes an exploratory high risk/high pay off R61 phase (three years).  Near the end of the R61 phase, NIDA scientific staff will review progress made towards the proposed R61 milestones and recommend a subset of R61 projects for continued support through the R33 phase (two years) pending merit and the availability of funds.  Applicants must propose both an R61 and an R33 phase in order to be responsive to this RFA.

 Vaccine Adjuvant Discovery Program NIAID-DAIT-NIHAI201700100

NIAID

The purpose of this program is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines by either (a) exploiting the natural capacity of the innate immune system to initiate and sustain effective T and B cell responses and to induce long term immune memory, or (b) acting directly on cells of the adaptive immune system to enhance their response to pathogen-derived antigens.

Burroughs Wellcome Fund/ASTMH Postdoctoral Fellowship in Tropical Infectious Diseases
American Society of Tropical Medicine and Hygiene
offered annually 
For more information, see list of previous recipients and Frequently Asked Questions.

NIH Funding Opportunity (R21) - Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms https://grants.nih.gov/grants/guide/pa-files/PAR-18-781.html

Deadline September 9, 2020

The purpose of this Funding Opportunity Announcement (FOA) is to support the use of Collaborative Cross (CC) mouse lines to advance understanding of the host genetics involved in immune regulation and function and to further develop CC mouse lines that more faithfully reproduce human immune responses. Applicants may include CC, CC derivatives with reproducible genomes and/or CC-RIX mice to accomplish these goals. Research areas supported by this FOA include immune system development, function or regulation; mechanisms governing immune response to infectious pathogens, vaccines or adjuvants; host susceptibility factors and mechanisms of pathogen-induced immunopathology; and immune mechanisms involved in the development and progression of immune-mediated diseases, such as allergy/asthma, autoimmunity, primary immunodeficiency, inflammation, and cell/organ/tissue transplant rejection or tolerance.

Ecology and Evolution of Infectious Diseases (EEID) NSF 16-592

A joint program of NSF, NIH, and USDA

 Deadline Third Wednesday in November, Annually Thereafter

This program supports research on the ecological, evolutionary, and socio-ecological principles and processes that influence the transmission dynamics of infectious diseases. Projects should be broad, interdisciplinary efforts focused on principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Examples of relevant work includes: the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the cultural, social, behavioral, and economic dimensions of disease transmission.

NRSA Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31) PA-18-666

NIH

Standard dates (expires January 8, 2021)

This program supports mentored research training leading to a doctoral degree in the biomedical, behavioral, or clinical sciences for individuals from diverse population groups, with the goal of enhancing diversity of the research workforce in the US.

High Priority HIV/AIDS Research within the Mission of the NIDDK (R01 Clinical Trial Optional)
PAS-18-698

National Institute of Diabetes and Digestive and Kidney Diseases

Standard AIDS deadlines (expires January 8, 2021)

This funding opportunity invites HIV/AIDS research projects within the mission of the NIDDK that address NIH's high priority HIV topics. Systemic complications of HIV infection directly affect many of the organ systems and processes within the research mission of the NIDDK (including diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases).  Moreover, NIDDK-relevant organs and tissues play central roles in HIV establishment, spread, persistence, and transmission. 

Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults

PAR-18-651, (R01, Clinical Trial Optional)

PAR-18-652, (R21, Clinical Trial Optional)

PAR-18-653, (R34 Clinical Trial Optional)

NIMH (all), NIDA (all), NIAID (R01 and R21 only) and NIMHD (R01 only)

Standard dates (expires January 8, 2021)

These opportunities encourage developmentally tailored research that incorporates recent advances in adolescent and young adult developmental research to optimize outcomes in HIV prevention and care research for this heterogeneous population. Applicants with preliminary data and/or planning to include longitudinal analysis may wish to apply using the R01 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. Applicants wanting to develop and pilot test an intervention may wish to apply using the R34 mechanism.

Support for Conferences and Scientific Meetings (Parent R13, Clinical Trial Not Allowed) PA-18-648

Many NIH Institutes including NIAID

Standard dates (expires January 8, 2021)

This opportunity supports high quality scientific conferences such as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge.

Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity
PA-18-754 (R21 Clinical Trial Not Allowed)
PA-18-753 (R01 Clinical Trial Optional)

NIAID

Standard AIDS deadlines (expires May 8, 2021)

The purpose of this FOA is to stimulate development of novel HIV biomarkers and new/improved HIV-1 incidence assays and algorithms to differentiate individuals with recent HIV-1 infections (within the previous year) from chronic infections.  The ideal assay(s) and/or algorithm(s) should provide 95% or greater specificity and increase reliability for distinguishing incident from chronic HIV infections, regardless of whether the incident or chronic cases are taking antiretroviral therapy (ART).

Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression
PA-18-738(R01 Clinical Trial Optional)
PA-18-739 (R21 Clinical Trial Optional)

NCI, NIA, NIDCR, and NINR

Standard dates (expires May 8, 2021)

The overall purpose of this FOA is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health
PA-18-722 (R01 Clinical Trial Optional)
PA-18-723 (R21 Clinical Trial Optional)

Multiple NIH Institutes including NIAID

Standard dates (expires May 8, 2021)

The NIAID is interested in supporting programs that support the development of biomedical measures to improve adherence to ART, PrEP, and other HIV prevention interventions and strategies.  NIAID is also interested in supporting basic and applied research in the behavioral and social sciences to inform the development of novel interventions that enable all HIV infected individuals to achieve durable viral suppression.

Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development
PA-18-724 (R21 Clinical Trial Not Allowed)
PA-18-725 (R01 Clinical Trial Not Allowed)

NIAID

Standard dates (expires May 8, 2021)

The purpose of this FOA is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.

NIAID Funding Opportunity (Presolicitation) - Large-scale T-cell immune epitope discovery 

https://www.fbo.gov/spg/HHS/NIH/NIAID/BAA-NIAID-DAIT-NIH-AI201800007/listing.html

Solicitation Number: BAA-NIAID-DAIT-NIH-AI201800007

Notice Type: Presolicitation

Introduction 

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (HHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology and Transplantation has a requirement for the discovery of T cell immune epitopes that are important in 1) protection of humans from infectious diseases 2) pathogenesis of autoimmune diseases and 3) and rejection of, or tolerance to, transplanted cells/organs/tissues. 

Description

The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, commensal organisms, or alloantigen, and validation of these epitopes regarding their role in immune protection or immune-mediated pathogenesis in humans. Investigators may also include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), or clinicians with expertise in the target autoimmune disease(s) or transplantation, as appropriate. This program will not support studies related to HIV/AIDS or allergen epitopes (including infection-related allergen epitopes). 

 Investigators may utilize established technological advances for immune epitope discovery or develop new or improved technologies for the large-scale identification of novel T cell epitopes. For the purpose of this solicitation, large-scale immune epitope discovery is defined as methods that will allow for extensive identification and validation of a broad range of novel T cell epitopes. Immune epitope discovery methods must be accompanied by basic studies in human samples to validate identified epitopes as targets of T cell recognition. Investigators may, but are not required to, include studies in appropriate animal models. Supported investigators will be required to attend an annual program progress meeting at NIH and submit their epitope information, and novel epitope prediction algorithms if applicable, to the Immune Epitope Database and Analysis Resource (www.iedb.org). Solicitations will be evaluated for their scientific and technical merit, scientific and technical personnel, project management plan, and facilities and other resources available to accomplish the proposed studies.

 It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about August 30, 2019.  NIAID estimates that the average annual total cost (direct and indirect costs combined) is $1M per contract award. However, it is anticipated that the total cost for the award(s) may vary depending upon the scope of the project and the technical objectives of the award(s). The length of time for which funding is requested should be consistent with the nature and complexity of the proposed research. In no event shall the period of performance proposed by an offeror exceed five years. 

 Any responsible offeror may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about May 8th, 2018, and may be accessed through FedBizOpps (https://www.fbo.gov/). This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.

For this solicitation, the NIAID requires proposals to be submitted via two methods: (1) 

Disc (CD or DVD) and (2) online via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable. 

DoD Peer Reviewed Medical Research Program 

The vision of the FY18 PRMRP is to improve the health and well-being of all military Service members, Veterans, and beneficiaries. The PRMRP challenges the scientific and clinical communities to address at least one of the FY18 PRMRP Topic Areas with original ideas that foster new directions along the entire spectrum of research and clinical care. The program seeks applications in laboratory, clinical, behavioral, epidemiologic, and other areas of research to advance knowledge in disease etiology, improve prevention, detection, diagnosis, treatment, and quality of life for those affected by a relevant disease or condition, and to develop and validate clinical care or public health guidelines.

 All applications for PRMRP funding must specifically address at least one of the Topic Areas as directed by Congress and must be directly relevant to the healthcare needs of military Service members, Veterans, and/or beneficiaries. Some Topic Areas of relevance:

  • Antimicrobial Resistance
  • Muscoskeletal Disorders
  • Hepatitis B and C
  • Vaccine Development for Infectious Diseases
  • Cardiomyopathy
  • Emerging Infectious Diseases
  • Inflammatory Bowel Diseases
  • Interstitial Cystitis
 

There are several awards available:

Focused Program Award

The PRMRP Focused Program Award mechanism is intended to optimize research and accelerate the solution for a critical question related to at least one of the Congressionally directed FY18 PRMRP Topic Areas through a synergistic, multidisciplinary research program. The anticipated total costs budgeted for the entire period of performance for an FY18 PRMRP Focused Program Award will not exceed $10M.

Investigator-Initiated Award

The PRMRP Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY18 PRMRP Topic Areas.  The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician's first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. The data may be unpublished or from published literature.

 Discovery Award

The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design.

 Technology Therapeutic Development Award

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, in at least one of the Congressionally directed FY18 PRMRP Topic Areas. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries.